EGFR and lung adenocarcinoma: EGFR‐mutant lung adenocarcinoma with coexisting TP53 mutations is more prone to exhibit whole‐genome doubling than EGFR mutations alone, often leading to copy‐number alterations and an increased likelihood of a mixed response [12].